Baricitinib is an orally administered selective JAK1 and JAK2 inhibitor that is JAK3-sparing. A total of 301 patients, with active RA on stable doses of methotrexate, were randomized
According to the agreement, a variety of glucagon presentations will be developed and commercialized including Biodel’s glucagon product candidate, a liquid formulation in an auto injector intended for
Dificlir, indicated to treat Clostridium difficile infections (CDI), is an orally administered, macrocyclic antibiotic that was developed by Optimer Pharmaceuticals. Astellas gained rights to develop and commercialize Dificlir
The designation was granted for the treatment and prophylaxis of bleeding episodes in patients with congenital factor IX deficiency (hemophilia B). CSL Behring research and development senior vice
With the acquisition, whose financing will be covered by existing funds, Sectra aims to expand its medical systems operations in the UK market. The cash purchase consideration amounts
The specialized module will optimize workflow and analysis pipeline when working with a huge number of antibodies during the development of new therapies including infectious diseases and cancer.
The settlement follows the Mylan litiagtion against the US Food and Drug Administration (FDA) regarding Mylan’s abbreviated new drug application for Modafinil Tablets, 100mg and 200mg. As a
The patent is entitled, Method for activating natural killer cells by tumor cell preparation in vitro and has a current expiration date of July 2027. CNDO-109 activates the
The Phase II trial will evaluate the clinical activity, safety and tolerability of multiple once-monthly doses of ALN-TTR02 in ATTR patients. Alnylam anticipates presenting data from the Phase
The company’s contract manufacturing organization is currently processing Epodure Biopumps for the treatment of anemia in a good manufacturing practice certified facility. Medgenics president and chief executive officer
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.